 LOS ANGELES--BUSINESS WIRE--CytRx Corporation OTCQB:CYTR CytRx or the Company, a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today highlighted that NantKwest, Inc. NASDAQ: NK NantKwest and ImmunityBio, Inc. ImmunityBio have announced that their ongoing Phase 2 clinical trials of a novel combination immunotherapy which include CytRxs licensed drug aldoxorubicin for locally advanced o 